In addition to pricing the biggest biotech IPO of the week, Braveheart Bio’s underwriters exercised their option to purchase more shares, boosting the clinical-stage company’s total haul to nearly $440 million. Braveheart’s lead drug could be competitive with a blockbuster Bristol Myers Squibb medicine for a type of cardiomyopathy.
The post Braveheart Bio’s $382M IPO for Heart Drug Leads a Big Week for Biotech IPOs appeared first on MedCity News.
